LLY Jun 2024 540.000 put
| Previous close | 1.1100 |
| Open | 1.1600 |
| Bid | 0.1000 |
| Ask | 0.6900 |
| Strike | 540.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.1600 - 1.1600 |
| Contract range | N/A |
| Volume | |
| Open interest | 178 |
- Yahoo Finance Video
Eli Lilly stock jumps on weight-loss drug sales forecast
Shares of Eli Lilly (LLY) are moving higher on Tuesday morning as the company reported its first-quarter earnings results, revealing a 26% year-over-year revenue increase in a figure of $8.77 billion. Ultimately, this revenue print fell short of estimates ($8.92 billion). The pharmaceutical giant did, however, raise its annual sales forecast by $2 billion due to an insatiable demand for its GLP-1 weight-loss drugs Mounjaro and Zepbound. Yahoo Finance Health Reporter Anjalee Khemlani joins Catalysts to break down the report and what it means for the company moving forward. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Nicholas Jacobino
Yahoo FinanceHow expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
The latest GLP-1 drugs are starting to see proof of greater use beyond diabetes and obesity. How will it affect makers Novo Nordisk and Eli Lilly?
BloombergLilly Soars as Forecast Boost Shows Weight-Loss Drugs’ Power
(Bloomberg) -- Eli Lilly & Co.’s shares soared as its brighter outlook for 2024 raised the potential ceiling for new weight-loss drugs even further in the eyes of analysts and investors.Most Read from BloombergHSBC CEO Quinn Unexpectedly Steps Down After Almost 5 YearsTesla Soars on Tentative China Approval for Driving SystemStocks Trade for 390 Minutes a Day. Increasingly, Only 10 MatterBinance and CZ’s Fortunes Are Set to Grow, Jail or no JailCocoa Plunges Most Ever With Trader Exodus Sparking
